Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon鈥檚 SEC filings are packed with technical clinical data, trial milestones, and intricate risk disclosures鈥攃rucial details that can overwhelm even seasoned biotech investors. Whether you want to track cash runway in the next Annexon quarterly earnings report 10-Q filing or need clarity on complex R&D footnotes, combing through hundreds of pages steals valuable time.
Stock Titan鈥檚 AI decodes every document the moment it hits EDGAR. Our platform delivers plain-English summaries of the Annexon annual report 10-K simplified, highlights critical sections of 8-K material events, and flags Annexon insider trading Form 4 transactions in real time. Searching 鈥�understanding Annexon SEC documents with AI鈥� or 鈥�Annexon earnings report filing analysis鈥� now leads you straight to concise insights, side-by-side with the original PDFs for deep dives.
Use the page to:
- Receive instant alerts on Annexon Form 4 insider transactions real-time鈥攅ssential when executives trade around trial readouts.
- Compare R&D spend and cash burn across quarters without scrolling through accounting tables.
- Study risk-factor shifts before financing rounds and partnerships via our AI-tagged 10-K and 10-Q excerpts.
- Review the latest Annexon proxy statement executive compensation details to gauge leadership incentives.
- See every Annexon 8-K material events explained, from clinical data releases to shelf registrations.
Stop wrestling with dense biotech language. Our AI-powered summaries, expert annotations, and comprehensive coverage of all filing types turn Annexon鈥檚 regulatory disclosures into actionable intelligence鈥攕o you can focus on investment decisions, not document mining.
Annexon, Inc. is a clinical-stage biopharma with no approved products and significant historical losses. The company is advancing three lead programs: tanruprubart for Guillain-Barr茅 Syndrome (GBS), which showed rapid and sustained functional improvement in a placebo-controlled Phase 3 trial and has Fast Track and orphan designations and a planned MAA submission in Europe in Q1 2026; vonaprument for geographic atrophy (GA), the only GA candidate to show significant vision preservation in Phase 2, with ARCHER II enrollment completed at 659 patients and topline data expected in H2 2026; and ANX1502, an oral C1s inhibitor with supportive Phase 1 PK/PD data and ongoing proof-of-concept study in cold agglutinin disease. The filing discloses recent equity offerings including pre-funded warrants (examples: 7,000,000 and 18,379,861 pre-funded warrants referenced) and ESPP availability of 2,959,996 shares. The company warns it will require substantial additional financing, relies on third-party manufacturers and collaborators, faces extensive regulatory and clinical risks, and has governance provisions that may limit stockholder control.
Annexon, Inc. Schedule 13G/A (Amendment No. 1) discloses that Logos Global entities and William Arsani filed jointly regarding Annexon common stock (CUSIP 03589W102) related to a reportable event dated 06/30/2025. The filing identifies five reporting persons: Logos Global Management LP, Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William, and provides the filer address at One Letterman Drive, Building C, Suite C3-350, San Francisco, CA 94129.
The statement states each reporting person beneficially owns 0 shares representing 0% of the class, with zero sole or shared voting or dispositive power. The reporting persons say they file jointly but disclaim membership in a group and disclaim beneficial ownership except to the extent of any pecuniary interest. The filing is signed by Arsani William on 08/13/2025.
Filing: Schedule 13G/A (Amendment No. 3) reporting beneficial ownership in Annexon Inc. (ANNX) as of 06/30/2025; signature dated 08/05/2025.
Key facts
- Reporting persons: FMR LLC and Abigail P. Johnson.
- Aggregate beneficial ownership: 15,695,226.36 shares, representing 14.3% of the class.
- Voting/dispositive powers reported: FMR LLC sole voting power 15,690,765.00; sole dispositive power 15,695,226.36; shared powers 0.00; Abigail P. Johnson reports sole dispositive power 15,695,226.36; no voting power.
Certification: Signatory certifies the securities are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 references included.
Annexon, Inc. (NASDAQ: ANNX) filed a Form 144 disclosing a proposed insider sale of up to 853 common shares, valued at approximately $2,226.42. The shares, representing roughly 0.0008% of the 109.7 million shares outstanding, were acquired through restricted-stock vesting on 07 Jul 2025 and are slated for sale on or about 14 Jul 2025 via Fidelity Brokerage Services LLC on the NASDAQ exchange.
No other sales by the filer in the past three months were reported, and the filing contains the standard affirmation that the seller possesses no undisclosed material adverse information. Filer name and relationship to the issuer were not provided, suggesting an administrative notice rather than a significant ownership change.
Given the minimal share count and dollar value, this transaction is considered routine and unlikely to affect Annexon鈥檚 capital structure, liquidity, or share price. Investors typically view such small-scale Form 144 filings as non-material disclosures.
Annexon, Inc. (ANNX) has filed a Form 144 indicating the planned sale of 1,117 common shares through Fidelity Brokerage Services on 14 July 2025. The shares, valued at an aggregate $2,880.97, were acquired via restricted-stock vesting on 11 July 2025 as compensation. Outstanding shares total 109,714,404; therefore, the proposed sale represents roughly 0.001% of shares outstanding, a de-minimis amount that will not affect float or control. No other sales have occurred in the past three months, and the filer affirms no undisclosed material adverse information.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
